Lytix Biopharma was represented by Øystein Rekdal (CSO Oncology) at SITC (the Society for Immunotherapy of Cancer) meeting 2014.

Saturday November 8^th, the company presented a poster (P264) showing the effect of LTX-315 on both treated and non-treated lesions in a rat sarcoma model. The title of the poster is: “Complete and specific regression of disseminated tumors in a novel rat mesenchymal three-tumor model after intralesional treatment with the nonapeptide LTX-315 (Oncopore^TM)”

See the poster